Research
Hormonal
GIP and GLP-1 may modify glucagon secretion, impacting cardiac substrate utilization.
Understanding the role of GIP and GLP-1 in glucagon secretion can help tailor treatments for cardiac health in T2D.
StrongSupportsmedium confidence
Not only do GIP and GLP-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization.
Why this rating
The statement is based on established hormonal interactions.
Source
Incretin-mediated control of cardiac energy metabolism
Jordan S. F. Chan et al. · Journal of Endocrinology · 2024
DOI 10.1530/joe-24-0011
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →